Mammalian tissues are fuelled by circulating nutrients, including glucose, amino acids, and various intermediary metabolites. Under aerobic conditions, glucose is generally assumed to be burned fully by tissues via the tricarboxylic acid cycle (TCA cycle) to carbon dioxide. Alternatively, glucose can be catabolized anaerobically via glycolysis to lactate, which is itself also a potential nutrient for tissues 1 and tumours [2] [3] [4] [5] . The quantitative relevance of circulating lactate or other metabolic intermediates as fuels remains unclear. Here we systematically examine the fluxes of circulating metabolites in mice, and find that lactate can be a primary source of carbon for the TCA cycle and thus of energy. Intravenous infusions of 13 C-labelled nutrients reveal that, on a molar basis, the circulatory turnover flux of lactate is the highest of all metabolites and exceeds that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice; lactate is made primarily from glucose but also from other sources. In both fed and fasted mice, 13 C-lactate extensively labels TCA cycle intermediates in all tissues. Quantitative analysis reveals that during the fasted state, the contribution of glucose to tissue TCA metabolism is primarily indirect (via circulating lactate) in all tissues except the brain. In genetically engineered lung and pancreatic cancer tumours in fasted mice, the contribution of circulating lactate to TCA cycle intermediates exceeds that of glucose, with glutamine making a larger contribution than lactate in pancreatic cancer. Thus, glycolysis and the TCA cycle are uncoupled at the level of lactate, which is a primary circulating TCA substrate in most tissues and tumours.
. The quantitative relevance of circulating lactate or other metabolic intermediates as fuels remains unclear. Here we systematically examine the fluxes of circulating metabolites in mice, and find that lactate can be a primary source of carbon for the TCA cycle and thus of energy. Intravenous infusions of 13 C-labelled nutrients reveal that, on a molar basis, the circulatory turnover flux of lactate is the highest of all metabolites and exceeds that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice; lactate is made primarily from glucose but also from other sources. In both fed and fasted mice, 13 C-lactate extensively labels TCA cycle intermediates in all tissues. Quantitative analysis reveals that during the fasted state, the contribution of glucose to tissue TCA metabolism is primarily indirect (via circulating lactate) in all tissues except the brain. In genetically engineered lung and pancreatic cancer tumours in fasted mice, the contribution of circulating lactate to TCA cycle intermediates exceeds that of glucose, with glutamine making a larger contribution than lactate in pancreatic cancer. Thus, glycolysis and the TCA cycle are uncoupled at the level of lactate, which is a primary circulating TCA substrate in most tissues and tumours.
Mammals generate energy by catabolizing food into carbon dioxide (CO 2 ). Glucose is generally assumed to be catabolized in cells via the concerted action of glyco lysis and the TCA cycle. Cells and tissues can also share metabolic tasks by exchanging intermediary metabolites, such as lactate. Here we systematically investigate the significance of different circulating metabolic intermediates. The circulatory turn over flux (F circ ) of a given metabolite refers to the rate at which tissues collectively consume the metabolite from the arterial circulation (F c ) and produce and excrete the metabolite into the venous circulation (F p ) (Fig. 1a) , with these two rates being equal at steady state. We considered whether there is any fundamental limit on which metabolites can have high F circ (that is, can contribute substantially to interorgan fluxes). For metabolite M, its consumption by the tissues cannot occur faster than the rate at which it is pumped from the heart:
circ Thus, only metabolites that are reasonably concentrated in blood can contribute substantially to interorgan fluxes, with 39 metabolites in mice having a sufficient concentration (greater than 30 μ M) to potentially have greater than 10% of the F circ of glucose 6 (Extended Data Fig. 1 ). We measured F circ for most of these species following an approach classically used to measure wholebody glucose production flux 7 : for each metabolite M, a trace amount of 13 Clabelled M is infused into the circulation at a constant rate R until steadystate labelling is achieved (Fig. 1b,c) , at which point the labelled fraction L is related to the turn over flux as:
circ For derivation, see Supplementary Note 1. Infusions were into the right jugular vein of freely moving C57BL/6 mice that had been fasted for 8 h (Extended Data Fig. 2a) , with measurements of serum labelling via liquid chromatography-mass spectrometry (LC-MS). Despite glu cose being widely assumed to be the predominant circulating carbon source, on a molar basis, lactate showed a 2.5fold higher circulatory turnover flux (1.25fold higher on a percarbonatom basis) ( Alanine basis) were pyruvate, glycerol, acetate, 3hydroxybutyrate, alanine and glutamine, each of which had a turnover flux less than 20% that of lactate (Table 1) . F circ of free palmitate was 15% that of glucose on a molar basis, which equals 40% on a carbon atom basis. Essential amino acids, which are not biosynthesized and come from either diet or tissue protein degradation, exhibited lower F circ values, which were propor tional to the abundances of the amino acids in protein (Fig. 1e) . Like lactate, infused pyruvate was rapidly consumed by tissues, but its circulating concentration is too low to carry comparable flux (equation (1) and Supplementary Note 1).
Previous F circ measurements have been largely restricted to glucose. However measurements have been reported for lactate and, consistent with our data, showed lactate turnover flux in excess of glucose turnover flux [8] [9] [10] [11] . The physiological significance of these measurements has generally been dismissed, on the basis of the assumption that high lactate turnover flux merely reflects rapid lactate-pyruvate exchange. In actuality, such exchange does not change the 13 Clabelling pattern of lactate and therefore does not contribute to turnover flux. Rather, the measured lactate circulatory turnover flux reflects the wholebody pyruvate production rate, multiplied by the fraction of tissue pyruvate that is excreted into the circulation as lactate (Supplementary Note 2 and Extended Data Fig. 3a) . Thus, high lactate F circ reflects a high fraction of tissue pyruvate being excreted as lactate (and a high fraction of tissue pyruvate being derived from circulating lactate).
Another concern with regards to prior measurements is differences in arterial and venous lactate labelling [12] [13] [14] [15] [16] . We modelled the origin of such differences using partial differential equations to examine label ling across a tissue capillary bed (Supplementary Note 1 and Extended Data Fig. 3b ). We find that the difference in arterial and venous labelling (L a − L v = Δ L) depends on the relative magnitude of F circ compared to metabolite flow:
a circ
In cases of substantial Δ L, F circ can be determined by equation (3) or by equation (2) with L the arterial metabolite labelling, with similar results (Supplementary Note 1). Thus, rather than precluding accurate determination of F circ , the arterial-venous difference in lactate labelling (Extended Data Fig. 3c ) confirms the high circulatory turnover flux of lactate.
To test the hypothesis that lactate is a primary circulating carbon carrier, we examined tissue metabolite labelling after infusing uniformly 13 Clabelled forms of the two primary carbon sources in cell culture (glucose and glutamine) or lactate. At steady state (Extended Data Fig. 4 ), the normalized labelling of a tissue metabolite from a circulating nutrient (L metabolite←nutrient ) is defined as the fraction of 13 C atoms in the metabolite, normalized to the fraction of 13 C atoms in the circulating nutrient [17] [18] [19] . As expected, normalized labelling of glycolytic and pentose phosphate intermediates in tissue was greatest from the glucose infusion, whereas tissue lactate was labelled substantially from both glucose and lactate tracer infusions (Extended Data Fig. 5 ). In most tissues, normalized labelling of TCA intermediates, as represented by malate and succinate (Extended Data Fig. 6 ), was greatest from the lactate infusion (Fig. 2a-c) .
Although normalized TCA labelling from lactate (L TCA←lac ) generally exceeded that from glucose (L TCA←glc ), the difference was, on average, modest (approximately 30% versus approximately 20%). A substantial fraction of serum lactate was, however, derived from glucose (red bar in Fig. 2b) . We denote the fraction of 13 C atoms in serum lactate following labelled glucose infusion, normalized to the fraction of 13 C atoms in serum glucose, as L lac←glc . Measurement of L TCA←lac and L lac←glc allows us to determine quantitatively how much of the TCA labelling from labelled glucose infusion actually arises through labelled circulating lactate (L TCA←lac ·L lac←glc ). This amount is shown as the solid line in Fig. 2d . Within the margins of error, TCA labelling from glucose is fully accounted for by labelling through circulating lactate in every tissue exept for the brain.
Analogously, labelled lactate infusion contributes to TCA labelling through labelled circulating glucose produced by gluconeogenesis n = 24 for lactate; n = 22 for glucose; n = 5 for glutamine; n = 4 for 3-hydroxybutyrate; n = 5 for palmitic acid; n = 4 for essential amino acids; n = 3 for others; mean ± s.d. 13 Clactate (a, n = 4), 13 Cglucose (b, n = 5), and 13 Cglutamine (c, n = 3). Data are mean ± s.d. d, Scatter plot of normalized labelling of TCA intermediates by infused 13 Cglucose versus infused 13 Clactate ( 13 Cglucose and 13 Clactate experiments performed separately). The solid line represents the expected labelling by 13 Cglucose assuming that glucose feeds the TCA cycle solely through circulating lactate. The dashed line indicates the expected labelling by 13 Clactate assuming that lactate feeds the TCA cycle solely through circulating glucose. Data are from a and b, each data point is one TCA intermediate in one tissue, mean ± s.d., n = 4 for 13 Clactate infusion and n = 5 for 13 (L TCA←glc · L glc←lac , dashed line in Fig. 2d ). To quantitatively delineate the direct flux contributions to the TCA cycle by circulating glucose, lactate, and glutamine, we developed a linear algebra model to com pute the direct TCA substrate usage of individual tissues ( Fig. 2e and Supplementary Note 3). This analysis confirmed that, except in the brain, direct glucose flux to the TCA cycle is close to zero in fasted mice. Glutamine and lactate together account for about half of TCA cycle carbon. It is likely that most of the remainder comes from a combi nation of other amino acids and fat. Thus, in the fasted state, glucose feeds the TCA cycle mainly via circulating lactate in all tissues but the brain.
At the wholebody level, the circulatory turnover fluxes of glu cose and lactate and their overall interconversion in body tissue can be quantitatively accounted for by a steadystate flux balance model (Supplementary Note 4), with fluxes determined solely on the basis of labelling of circulating glucose and lactate. In fasting mice, modelling revealed that the majority of glucose enters the TCA via circulating lactate (Fig. 2f) . Similar relative contributions of glucose and lactate were also observed in anaesthetized mice (Extended Data Fig. 7) .
We next examined fluxes of glucose and lactate in fed mice, where insulin signalling could increase tissue glucose metabolism. Indeed, F circ for glucose was 3.1fold higher than in fasted mice. This was accompanied by a small increase in F circ for lactate, which was about 1.1fold of F circ for glucose on a molar basis (55% on a percarbonatom basis) (Fig. 3a) . TCA labelling from glucose also increased (Extended Data Fig. 8) , with glucose and lactate making a roughly equal direct contribution to the muscle TCA cycle. In other organs, even in the fed state, glucose contributes to the TCA cycle mostly through circulating lactate (Fig. 3b, c) . Quantitative wholebody modelling showed that, in the fed state, about 40% of glucose feeds the TCA cycle through circulating lactate (Fig. 3d and Supplementary Note 4). Further work is required to assess other states, such as exercise, and to identify the tissue compartments responsible for glucosetolactate flux.
Rapid glucose catabolism to lactate was the first molecular phenotype assigned to cancer 20, 21 . Tumours are often thought of as having an iso lated metabolic microenvironment owing to poor perfusion, in which local exchange of nutrients (for example, between cancer cells and stro mal cells) predominates over nutrient exchange with the circulation. We measured TCA substrate contributions in three genetically engineered mouse models (GEMMs). Notably, in all three cases, the contribu tion of circulating lactate to tumour TCA intermediates exceeded that of glucose by about twofold (Fig. 4a-c) , with quantitative analysis consistent with glucose contributing to the tumour TCA cycle only through circulating lactate (Extended Data Fig. 9 ). Thus, the GEMM tumours that we studied are thoroughly perfused by lactate. This does not rule out the potential for some sections within human tumours to be less well perfused 5 or for an important subset of tumour cells to be isolated within a poorly perfused metabolic niche. Note that in normal lung tissue and lung cancer, the largest TCA contribution was from lactate, whereas in the pancreas and pancreatic cancer, glutamine contributed more (Figs 2e and 4d), consistent with tumours mirroring the substrate preferences of their tissues of origin 22, 23 . It is useful to differentiate between the above conclusions that arise directly from experimental data and those that are inferred on the basis of quantitative modelling, which omits certain biological complexity, such as tissue heterogeneity. The experimental data demonstrate that circulating lactate is a major source of TCA intermediates. The quanti tative modelling leads to the additional conclusion that, in most tissues and GEMM tumours, the contribution of glucose to the TCA cycle is mostly through circulating lactate.
The metabolic role of lactate is well recognized, including as a fuel for tissues 24 and tumours [2] [3] [4] [5] 25 . In the classical Cori cycle, muscle produces lactate which is then taken up by the liver for gluconeogenesis. Previous work has highlighted the potential for lactate to shuttle carbon both between and within tissues [26] [27] [28] [29] . We find that such shuttling under lies the majority of circulating lactate turnover, with glucose feeding TCA metabolism mainly through circulating lactate (Fig. 4e) . This picture requires high lactate dehydrogenase (LDH) activity and rapid lactate transport across the plasma membrane. Mammals encode two ubiquitously expressed LDH isozymes (LDHA and LDHB), as well as four monocarboxylate transporters (MCT1-MCT4). While the dif ferent isozymes show some kinetic differences, the direction of net flux is determined by thermodynamics. Genetic manipulation of these a, Turnover fluxes of glucose, lactate, and glutamine in fed and fasted mice (fed state: n = 5 for glucose, n = 12 for lactate, and n = 6 for glutamine; fasting state: n = 22 for glucose, n = 24 for lactate, and n = 5 for glutamine).
Data are mean ± s.d., * * * * P < 0.0001; * * P < 0.002 by ttest. b, Normalized labelling of TCA intermediates by 13 Cglucose versus 13 Clactate, as in enzymes and transporters will be important to establish the biochem ical basis of the phenomena reported here.
Among the many metabolic intermediates, why does lactate carry high flux? Lactate is redoxbalanced with glucose. The rapid exchange of both tissue lactate and pyruvate with the circulation may help to equate cytosolic NAD + /NADH ratios across tissues, allowing the whole body to buffer NAD(H) disturbances in any given location 30 . Nearly complete lactate sharing between tissues effectively decouples glyco lysis and the TCA cycle in individual tissues, allowing independent tissuespecific regulation of both processes. Because almost all ATP is made in the TCA cycle, each tissue can acquire energy from the largest dietary calorie constituent (carbohydrate) without needing to carry out glycolysis. In turn, glycolytic activity can be modulated to support cell proliferation, NADPH production by the pentose phosphate pathway, brain activity, and systemic glucose homeostasis 21 . In essence, by having glucose feed the TCA cycle via circulating lactate, the housekeeping function of ATP production is decoupled from glucose catabolism. In turn, glucose metabolism is regulated to serve more advanced objec tives of the organism. 
MeThODS

Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized. Intravenous infusion of wild-type C57BL/6 mice. Animal studies followed pro tocols approved by the Princeton University Institutional Animal Care and Use Committee. In vivo infusions were performed on 12-14weekold C57BL/6 mice precatheterized in the right jugular vein (Charles River Laboratories). Mice were randomly chosen for infusions of different tracers. No blinding was performed. A minimum of three mice was used for each tracer. To collect arterial blood sam ples, we used mice precatheterized in both the right jugular vein and left carotid artery (Charles River Laboratories), infusing through the venous catheter and drawing blood from the arterial catheter. Venous samples were taken from tail bleeds. The mice were on a normal light cycle (8:00-20:00). On the day of the infusion experiment, mice were transferred to new cages without food around 8:00 (beginning of their sleep cycle) and infused for 2.5 h starting at around 14:00. To analyse the fed state, the mice were maintained without food until around 19:00, at which time chow was placed back in the cages and the 2.5 h infusion initiated. The mouse infusion setup (Instech Laboratories) included a tether and swivel system so that the animal had free movement in the cage. Watersoluble isotopelabelled metabolites (Cambridge Isotope Laboratories) were prepared as solutions in sterile normal saline and infused via the catheter at a constant rate for 2.5 h (unless otherwise indicated). To make 13 Cpalmitate solution, [U ) was infused into 8h fasted mice for 2.5 h. Blood samples were collected from the tail vein and facial vein for measure ment of serum enrichment of isotopic tracers. Mice were euthanized by cervical dislocation and tumours were quickly snap frozen in liquid nitrogen using a pre cooled Wollenberger clamp. Throughout the experiments, mice were examined for evidence of distress due to lung tumour progression (for example, difficulty breathing, difficulty moving, significant weight loss, or moribund status) every day to ensure the health and wellbeing of the animal. Any animals exhibiting signs of distress would have been euthanized. At the time of in vivo infusion, none of the mice showed signs of distress.
Animal studies with the pancreatic cancer GEMM followed protocols approved by the University of California at San Diego Institutional Animal Care and Use Committee. ) was infused into 8h fasted mice for 2.5 h. Blood samples were collected from the tail vein for measurement of serum enrich ment of isotopic tracers. Mice were euthanized by cervical dislocation, and tumours were quickly snap frozen in liquid nitrogen using a precooled Wollenberger clamp. Throughout the experiments, tumour progression was monitored according to protocols approved by the University of California San Diego Institutional Animal Care and Use Committee: weekly (for no visible, palpable, clinical, or behavioural signs of tumour burden), twice weekly (for visible or palpable tumours; changes in appearance or behaviour), and/or daily (for any signs of morbidity or mortality). It is important to note that with our pancreatic cancer model, in most instances, the mice show no visible signs of disease-no palpable tumour, no lethargy, no hunch ing, no weight loss, although we monitored carefully for these signs of distress.
Metabolite measurement. Metabolites were extracted from serum samples (thawed on ice) by adding 65 μ l 80:20 methanol:water solution at − 80 °C to 5 μ l of serum sample, followed by vortexing for 10 s, incubation at 4 °C for 10 min, and centrifugation at 4 °C and 16,000g for 10 min. To extract metabolites from tissue samples, frozen tissue samples were first weighed (~ 20 mg each sample) and ground using a Cryomill (Retsch). The resulting powder was then mixed with − 20 °C 40:40:20 methanol:acetonitrile:water solution, followed by vortexing for 10 s, incubation at 4 °C for 10 min, and centrifugation at 4 °C and 16,000g for 10 min. The volume of the extraction solution (in μ l) was 40× the weight of tissue (in mg). The supernatant was transferred to LC-MS autosampler vials for analysis.
Serum and tissue extracts were analysed using LC-MS. In brief, a quadrupole orbitrap mass spectrometer (Q Exactive Plus, Thermo Fisher Scientific) operat ing in negative ion mode was coupled to hydrophilic interaction chromatography via electrospray ionization and used to scan from m/z 73 to 1,000 at 1 Hz and 140,000 resolution. LC separation was achieved on a XBridge BEH Amide column (2.1 mm × 150 mm, 2.5 μ m particle size, 130 Å pore size; Waters) using a gradi ent of solvent A (20 mM ammonium acetate + 20mM ammonium hydroxide in 95:5 water:acetonitrile, pH 9.45) and solvent B (acetonitrile). Flow rate was 150 μ l min N. Circulating glycerol labelling was determined by first converting serum glycerol to glycerol 3phosphate using glycerol kinase and then measuring the labelling of glycerol 3phosphate with LC-MS.
For acetate, circulating metabolite labelling was determined by GC-MS using a 7890A GC system coupled to a 5975 MSD mass spectrometer (Agilent) after deri vatization with 2,3,4,5,6pentafluorobenzyl bromide as described 36 . GC separation was achieved using an Agilent J&W 1227033 column (30 m × 0.25 mm × 0.5 μ m). The GC temperature program was: 0 min, 35 °C; 6 min, 35 °C; 12 min, 220 °C; 17 min, 220 °C, followed by returning to 35 °C for the next injection. Other GC parameters were: injection volume 1 μ l; He as carrier gas at a flow rate of 1.2 ml min −1 ; inlet temperature 250 °C; transfer line temperature 280 °C. Mass spectrometry detection was in electron impact ionization mode, with SIM scans of m/z 240.3 and 242.3 for unlabelled and 13 C 2 acetate, respectively. Free fatty acids in serum samples (thawed on ice) were extracted by adding 200 μ l ethyl acetate at room temperature to 10 μ l serum samples, followed by vortexing for 10 s, incubation at 4 °C for 10 min, and centrifugation at 16,000g for 10 min. The top layer of approximately 190 μ l was transferred to a new glass vial before being dried under nitrogen gas flow. The dried extract was dissolved in 100 μ l 1:1 isopopanol: methanol before being loaded onto the LC-MS. MS analysis was conducted on an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific) scanning at 1 Hz and 100,000 resolution operating in negative ion mode. LC separation was on reversedphase ionpairing chromatography on a Luna C8 column (150 × 2.0 mm, 3 μ m particle size, 100 Å pore size; Phenomenex) with a gradient of solvent A (10 mM tributylamine + 15 mM acetic acid in 97:3 water:methanol, pH 4.5) and solvent B (methanol). Flow rate was 250 μ l min 13 C-glucose and 13 C-lactate. a, Normalized labelling by 13 Cglucose in fasting mice (n = 3 for pyruvate, 2oxoglutarate, and 3phosphoglycerate, n = 4 for alanine, and n = 5 for all other metabolites; mean ± s.d.). b, Normalized labelling by 13 Clactate in fasting mice (n = 3 for 3phosphoglycerate and n = 4 for all other metabolites; mean ± s.d.). n indicates the number of mice. For the lactate tracer studies, venous serum and tissue labelling are normalized to the arterial serum lactate labelling. Note that citrate, malate and succinate in tissues turn over sufficiently slowly that labelling is robust to the small (< 90 s) delay between euthanizing the mouse and tissue harvesting. This delay may, however, result in erroneous measurements for tissue lactate, pyruvate and glycolytic intermediates. Analyses in the main text are limited to the better validated measurements of serum metabolites and tissue TCA intermediates. With this caveat in mind, it is nevertheless intriguing that lactate labelling varies markedly across tissues. After labelled glucose infusion, lactate labelling is highest in the brain, consistent with its use of glucose as a major substrate. In the kidneys lactate is strongly labelled after glucose infusion, even though TCA intermediates are more labelled after lactate infusion. A potential explanation involves tissue heterogeneity; for example, the presence both of glycolytic cells that make lactate from circulating glucose and of oxidative cells that make TCA intermediates from circulating lactate. In other tissues, such as liver, tissue lactate labelling is far below circulating lactate and very similar to TCA labelling; this may reflect mixing of carbon between lactate and TCA intermediates via gluconeogenesis or pyruvate cycling. Another factor diluting tissue lactate labelling is that, as blood passes through tissue, owing to the rapid exchange between tissue and circulating lactate, the circulating lactate loses its labelling, as is evident from the lactate arteriovenous labelling difference.
